Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer.
TGFβ is reportedly responsible for accumulation of CD4(+)Foxp3(+) regulatory T cells (Tregs) in tumor. Thus, we treated mouse 4T1 mammary carcinoma with 1D11, a neutralizing anti-TGFβ (1,2,3) antibody. The treatment delayed tumor growth, but unexpectedly increased the proportion of Tregs in tumor. I...
Main Authors: | Xin Chen, Yuan Yang, Qiong Zhou, Jonathan M Weiss, Olamae Zack Howard, John M McPherson, Lalage M Wakefield, Joost J Oppenheim |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3887137?pdf=render |
Similar Items
-
Eradication of Established Murine Skin Tumors by Cyclic Chemoimmunotherapy with Cyclophosphamide and Effector T Cells
by: Koh Nakata, et al.
Published: (2011-01-01) -
Immunophenotypic and functional analyses of a cyclophosphamide-induced LGL population in immunised rats : potential for chemoimmunotherapy of tumours
by: Stewart, Lorna S.
Published: (1990) -
Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
by: Hui Zhong, et al.
Published: (2020-01-01) -
Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
by: Tomotaka Suzuki, et al.
Published: (2021-08-01) -
THE CHEMOIMMUNOTHERAPY BASED ON DENDRITIC CELLS AND CISPLATIN IN EXPERIMENT
by: Gorbach O. I., et al.
Published: (2014-08-01)